Eastport Critical Metals Corp. will present at the Kinvestor Day 2026 Virtual Investor Conference on October 22, 2026. CEO Daniel Major will provide updates on the company's six-project portfolio in Botswana, including key assets like the Matsitama Copper Project and the Semarule Rare Earth Elements Project. The presentation aims to inform investors about recent progress and upcoming catalysts in Eastport's critical minerals development efforts. This event offers a platform for Eastport to reach a broad audience of resource investors and engage in live Q&A sessions.
Eastport Critical Metals' upcoming presentation at Kinvestor Day 2026 provides context for resource investors. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 21, 2026 00:51 WIB: Of 83 priced US stocks in the sector, 52 rose and 31 fell. Notable movers include AVNT at USD 40.51 (+2.53%), CTVA at USD 12.97 (+2.53%) with 89% buy order activity, and SLI at USD 1.50 (+2.38%) with 79% buy order activity.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
